Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesMecamylamine ? a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders
Expert Opinion in Pharmacotherapy, 11/02/09
Bacher I et al. – Two independent Phase II clinical trials recently confirmed mecamylamine's hypothesized antidepressant activity and suggest that it may be effective as an augmentation pharmacotherapy for SSRI treatment resistant major depression. These areas of investigation for mecamylamine are reviewed and recommendations for future research directions are proposed.
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/29/09
Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09
Outcome of intracerebral haemorrhage patients pre-treated with statins
European Journal of Neurology, 11/17/09
Sponsor
Article Search
Sponsor